InvestorsHub Logo
Followers 28
Posts 4760
Boards Moderated 3
Alias Born 04/05/2017

Re: December1981 post# 26357

Friday, 04/20/2018 12:31:31 PM

Friday, April 20, 2018 12:31:31 PM

Post# of 33238
Revenue projection is hard to estimate.
I had posted a message here, earlier in the year, an estimated analysis of what Rio Grande might have been selling before ENDV acquired the assets. It did appear to be a very significant amount. But then again RGN was on the downhill slide.

Opioid epidemic is the buzz term of the year. Lots of news about it. Even lawsuits popping up.
This new avoidance of overly prescribing/using opioids can possibly open the doors wider for the acceptance/use of Sofpulse.

ENDV should market the heck out of Sofpulse for chronic wounds with the elderly. It is approved by Centers for Medicare and Medicaid. Let's have the Gov't become a big customer.
Problem is changing the mindset of doctors and competing with pharmaceutical companies giving sales/use incentives to Doctors.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENDV News